REGENXBIO Quarterly Cash Flow Statement
NASDAQ: RGNXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
REGENXBIO free cash flow
In the quarter ended Jun 30, 2026, REGENXBIO generated -$62.2 million of operating cash flow and spent $760,000 on capital expenditures. That left free cash flow of -$63.0 million, a free-cash-flow margin of -58.3% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
REGENXBIO cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 22.71M | -90.05M | -67.15M | -61.94M | -70.87M | 6.08M | -51.19M | -59.60M | -52.99M | -63.33M | -62.89M | -61.87M |
| Net Income growth (YoY) | — | -1580.37% | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 3.76M | 3.86M | 3.87M | 3.89M | 3.90M | 3.96M | 4.02M | 3.96M | 4.05M | 4.18M | 4.33M | 4.37M |
| Stock-Based Compensation | 9.05M | 8.62M | 8.38M | 9.00M | 8.65M | 8.54M | 9.54M | 9.88M | 9.44M | 9.60M | 8.34M | 10.22M |
| Change in Working Capital | -105.55M | 17.88M | -7.42M | -9.03M | -1.95M | 34.74M | 11.20M | 2.59M | -21.76M | 14.74M | 4.42M | 3.66M |
| Operating Cash Flow | -62.24M | -76.19M | -52.29M | -55.96M | -49.34M | 33.63M | -31.62M | -40.55M | -45.50M | -55.45M | -40.76M | -49.41M |
| Capital Expenditures | -760.00K | -1.24M | -508.00K | -491.00K | -391.00K | -1.02M | -1.08M | -326.00K | -474.00K | -557.00K | -1.13M | -1.44M |
| Investing Cash Flow | 65.92M | 70.59M | 37.54M | 42.29M | -140.44M | 44.74M | 40.27M | 50.26M | -268.00K | 13.18M | 33.97M | 38.66M |
| Financing Cash Flow | 17.57M | -13.64M | -9.58M | -7.08M | 139.23M | -5.79M | -7.74M | -10.86M | -9.45M | 120.72M | -11.96M | -4.80M |
| Net Change in Cash | 21.26M | -19.24M | -24.34M | -20.76M | -50.55M | 72.58M | 909.00K | -1.15M | -55.21M | 78.45M | -18.75M | -15.55M |
| Free Cash Flow | -63.00M | -77.42M | -52.80M | -56.45M | -49.73M | 32.60M | -32.70M | -40.88M | -45.97M | -56.01M | -41.89M | -50.85M |
This table shows 12 quarterly periods of REGENXBIO's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RGNX's reporting calendar. What is a cash flow statement?